Covid19
Conditions
Keywords
HLA-G
Brief summary
The aim of the research is to study the immune checkpoint linked to the HLA-G molecule in the dysregulation of the control of COVID-19 infection.
Detailed description
Single-center, prospective, open-ended, interventional study with minimal risks and constraints. Patients will be divided into 3 groups: patients not infected with COVID-19, patients infected with COVID-19 not hospitalized, patients infected with COVID-19 hospitalized.
Interventions
OTHERBaseline and during hospitalization blood samples
Blood sample will be performed at the inclusion visit for all patient and for the hospitalized COVID-19 infected patients, extra-blood samples will be performed : * at day 3 * day 5 and * In case of aggravation * At the discharge from hospital
Blood sample will be performed at the inclusion visit only
Sponsors
Hopital Foch
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patient with possible or confirmed infection by COVID-19
Exclusion criteria
* Patient without liberty or guardianship
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Comparison of the percentage of T cells expressing the HLA-G receptor ILT2 (CD3+CD4+ILT2+ T cells, and CD3+CD8+ILT2+ T cells) between the 3 groups of patients. | 1 month | The CD3 + T lymphocyte cell populations (CD4 + ILT2 + and CD8 + ILT2 +) will be compared between the groups of patients |
| Comparison of the expression of circulating soluble HLA-G, between the groups of patients. | 1 day | Blood levels of soluble HLA-G and plasma microvesicles with expression of HLA-G will be compared between the groups of patients. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| 1 month survival | 1 month | Vital status collected 1 month post inclusion for all the patients |
| Assessment of the severity of the disease according to the isoform of HLA-G | 1 month | Comparison of the isoforms (alleles) of HLA-G regarding the severity of the disease for the infected patients. |
| Comparison of the expression of one of the cell receptors of the SARS-CoV-2 virus, called BSG (Basigin), whose expression is modified by the interaction between HLA-G. | 1 day | The expression of the BSG cell receptor induced by HLA-G will be compared between COVID19 patients and uninfected patients. |
Countries
France
Outcome results
None listed